On December 26, Guangzhou Zhengyuan Biotechnology, hereinafter referred to as Zhengyuan Biotechnology) and Academician Yan Xiaojun jointly established Guangzhou Xiaojun Biomedical Science and Technology, with Academician Yan Xiaojun as the chief scientist, and the original scientific research results conference was a complete success in Zhengyuan Biological Base in Guangzhou, Guangdong Medical Valley, China.
Guangzhou Zhengyuan Biotechnology Co., Ltd. is a company that lays out the whole industry chain of biotechnology, with life banking and cell storage business in the upstream, stem cell and cell-free preparation and bioengineering technology research and development in the midstream, and clinical transformation of cell technology into health management and disease intervention in the downstream.
Since its establishment, Zhengyuan Biotech has become a star of rapid development among high-tech enterprises in China. The management team has improved the layout from high-dimensional strategy and top-level design, and quickly realized the talent echelon reserve. At the same time, the combination of production, education and research has laid a solid foundation for the development of our company, and more than 30 original independent intellectual property patents have been obtained. A major breakthrough has been made in the research and development of mesenchymal stem cells, and five types of directional differentiation technologies and the establishment of a first-class cell bank have been completed, and the clinical application of transformation data is leading the industry. Zhengyuan Biotech has been committed to the research of human life and health, with regenerative medicine technology as the core, and working with major biomedical companies and famous experts and professors around the world to jointly promote cell clinical, gene medicine research, and regenerative medicine technology applications. In the field of stem cell application, it has been focusing on the prevention of chronic diseases and has been highly praised by peer experts.
Academician Yan Xiaojun is one of the earliest scientists engaged in the research and development of genetic diagnosis technology in China, and the combined biochip preparation technology developed by him won the 2005 National Invention Patent Gold Medal and the World Intellectual Property Organization Gold Medal, which is the highest level of intellectual property award in the field of biochip research in China so far. After more than 20 years, Academician Yan Xiaojun has mainly devoted himself to the research and development of targeted substances based on DC cells, and has formed important achievements represented by active hepatitis B vaccine, interventional cervical cancer vaccine and targeted nasopharyngeal cancer vaccine, and has been successfully applied in clinical practice. Among them, the ** liver cancer vaccine obtained the orphan drug qualification of the US FDA for liver cancer in 2018, and the new drug application will be launched in China in 2022. He has undertaken more than 30 major projects at or above the provincial and ministerial level, more than 50 patents, published more than 300 articles, including more than 40 SCI articles, edited and published 7 monographs, and won more than 20 awards at or above the provincial and ministerial level.
Xie Jiaqi, chairman of Zhengyuan Biotech, said that in the future, the company will join hands with Academician Yan Xiaojun to make greater contributions to the cause of human health, based on the Greater Bay Area, radiating the whole country, looking at the world, and building a global unicorn enterprise in China's biotechnology.